Flagyl is available in doses for adults as tablets of 250 mg, 500 mg, and 750 mg. The dose for pediatric patients is available as tablets of 35 to 50 mg/kg/24 hours. Patient dosage administration depends upon the severity of infection caused by parasites or bacteria, and any other existing medical conditions, particularly if they are severe. There are several drug interactions with Flagyl. Interactions, for example, like warfarin (Coumadin, Jantoven), cimetidine (Tagamet), cholestyramine (Questran, Questran Light), amprenavir (Agenerase), lithium (Eskalith, Lithobid), and cyclosporine. This medicine may cause increased heart rate, which can lead to seizures. Ask your doctor, pharmacist, or other medical professional if you have questions about Flagyl.
In controlled clinical trials , the total incidence of adverse reactions associated with the use of METROCREAM® (metronidazole topical cream) Topical Cream was approximately 10%. Skin discomfort (burning and stinging) was the most frequently reported event followed by erythema , skin irritation, pruritus and worsening of rosacea . All individual events occurred in less than 3% of patients. The following additional adverse experiences have been reported with the topical use of metronidazole: dryness, transient redness, metallic taste, tingling or numbness of extremities and nausea .
Use of PENLAC® NAIL LACQUER (ciclopirox) Topical Solution, 8%, for 48 additional weeks was evaluated in an open-label extension study conducted in patients previously treated in the vehicle-controlled studies. Three percent (9/281) of subjects treated with PENLAC® NAIL LACQUER (ciclopirox) Topical Solution, 8%, experienced at least one TEAE that the investigator thought was causally related to the test material. Mild rash in the form of periungual erythema (1% [2/281]) and nail disorders (1% [4/281]) were the most frequently reported. Four patients discontinued because of TEAEs. Two of the four had events considered to be related to test material: one patient's great toenail "broke away" and another had an elevated creatine phosphokinase level on Day 1 (after 48 weeks of treatment with vehicle in the previous vehicle-controlled study).